BioSpace News Archive

FDA

AAN Spotlight: Multiple System Atrophy, Migraine, ALS and Parkinson’s

The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.

April 7, 2022
·
4 min read
·
Mark Terry
Business

ENSEM Therapeutics Banks $67 Million in Search of New Drug Targets

Proceeds from the Series A will be used to further advance the company’s Kinetic Ensemble platform and accelerate its R&D pipeline.

April 7, 2022
·
2 min read
·
Alex Keown
Business

Sanofi Closes NY Kadmon Facility in Effort to Simplify Operations

Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing Kadmon’s New York facility. As part of the paring down, Sanofi is also laying off 25 employees at the location.

April 7, 2022
·
2 min read
·
Hannah Chudleigh
Triana Raises $110M to Solve Undruggable Cancer Targets with Molecular Glue

Triana Biomedicines leaped out of stealth mode with $110 million in Series A financing that will be used to fund its mission to discover and develop novel small molecules to treat diseases.

April 7, 2022
·
2 min read
·
Alex Keown
Business

BioSpace Movers & Shakers, April 8

Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.

April 7, 2022
·
10 min read
·
Alex Keown
Drug Development

At AAN, Janssen Shows IgG Levels are Effective Biomarker for Generalized Myasthenia Gravis Treatments

Janssen’s Phase II study of nipocalimab for generalized myasthenia gravis (gMG) shows that serum IgG levels can be used as a supportive biomarker to manage this disease.

April 7, 2022
·
4 min read
·
Gail Dutton
Drug Development

A Week After Anemia Drug Rejection, Akebia Lays Off 42% of Workforce

In a regulatory filing, the Cambridge, Massachusetts-based company indicated that it plans to “refocus its strategic priorities” and lay off 42% of its workforce.

April 7, 2022
·
2 min read
·
Mark Terry
Genetown

Medicare Officially Restricts Coverage of Biogen’s Aduhelm

Shares of Biogen are falling in post-market trading after the U.S. government officially announced it will limit coverage of the company’s controversial Alzheimer’s drug Aduhelm to patients in clinical trials.

April 7, 2022
·
3 min read
·
Alex Keown
Out of Office: a Comprehensive Guide to Vacation Days and PTO (Paid Time Off)

If your personal life has taken a backseat, it might be time to use your paid time off. Learn everything you need to know about PTO and how to request it in our guide.

April 7, 2022
·
5 min read
·
Franklin Carpenter
Cognitive and Memory Enhancer Drugs Market – Growth Expansion Opportunities in the Global Market

The cognitive and memory enhancer drugs market has been anticipated to grow at a significant pace throughout the forecast period.

April 7, 2022
·
5 min read